Project Grant R44CA298498
Award Date 9/22/25
Completion Date 8/31/27
Dollars Obligated $919K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85719, USA
Similar Awards
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,064,642 to Tufts Medical Center Parent, Inc. to conduct research on the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling pathway in regulating glioma stem cell properties and preventing recurrence of glioblastoma (GBM), a deadly form of brain cancer. The research aims to characterize how the ANG-PLXNB2 axis promotes small RNA biogenesis, particularly tRNA-derived...
- The federal Project Grant award of $2,820,337, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 6, 2025, supports research to develop new methods for directly measuring and interrupting metabolic pathways in glioblastoma brain cancers. The project, led by researchers at the University of Michigan, aims to: 1) create new techniques to directly measure metabolic activity in mouse models and glioblastoma patients, and 2) conduct a clinical trial to...
- This $305,031 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Round Table Research, Inc. (UEI: N3Q3CN6FZDV5) supports the development of engineered extracellular vesicle (EV) therapies for treating the aggressive brain cancer glioblastoma (GBM). Specifically, the project aims to advance EV therapy towards Investigational New Drug (IND) application by conducting pre-IND-enabling toxicity, biodistribution, and safety studies, as well as...
- The National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health, awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Case Western Reserve University in Cleveland, OH. The grant supports research to study the regulation of translation (mRNA-to-protein) in glioblastoma stem-like cells as a mechanism of adaptation to the hypoxic tumor microenvironment. The research approach uses...
- This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...
- This $462,153 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Northern Michigan University (NMU) will support research to develop and utilize a novel genetically encoded fluorescent biosensor, called D2HGLO, to quantify intracellular concentrations of the oncometabolite D-2-hydroxyglutarate (D-2-HG) in intact cells. D-2-HG accumulates at high levels in cancers with mutations in the isocitrate dehydrogenase (IDH) enzymes, which are known to...
- The National Cancer Institute (NCI) awarded a $170,655 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University to develop a new molecular method for mapping protein trafficking between glioblastoma (GBM) cells and other brain cell populations in an in vivo setting. The 2-year project, running from July 1, 2025 to June 30, 2027, aims to create an esterase-activated bioorthogonal reaction system to precisely record protein translocation...
- This $399,358 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cordance Medical Inc. aims to optimize a non-invasive focused ultrasound system, called the "NeuroAccess System," to enable liquid biopsies for brain tumor patients. The key objectives are to demonstrate the safety of repeatedly opening the blood-brain barrier, optimize the opening volume and technique in a rat glioma model, and confirm the system's ability to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...